Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

KODK vs AMGN vs GILD vs XRX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
KODK
Eastman Kodak Company

Specialty Business Services

IndustrialsNYSE • US
Market Cap$1.38B
5Y Perf.+470.6%
AMGN
Amgen Inc.

Drug Manufacturers - General

HealthcareNASDAQ • US
Market Cap$177.59B
5Y Perf.+43.3%
GILD
Gilead Sciences, Inc.

Drug Manufacturers - General

HealthcareNASDAQ • US
Market Cap$166.40B
5Y Perf.+72.2%
XRX
Xerox Holdings Corporation

Information Technology Services

TechnologyNASDAQ • US
Market Cap$310M
5Y Perf.-85.1%

KODK vs AMGN vs GILD vs XRX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
KODK logoKODK
AMGN logoAMGN
GILD logoGILD
XRX logoXRX
IndustrySpecialty Business ServicesDrug Manufacturers - GeneralDrug Manufacturers - GeneralInformation Technology Services
Market Cap$1.38B$177.59B$166.40B$310M
Revenue (TTM)$1.09B$37.24B$29.73B$7.41B
Net Income (TTM)$-137M$7.80B$9.22B$-1.04B
Gross Margin22.4%71.5%63.0%25.7%
Operating Margin3.6%31.6%38.2%-0.6%
Forward P/E14.7x15.7x5.1x
Total Debt$250M$54.60B$24.59B$4.25B
Cash & Equiv.$337M$9.13B$7.56B$512M

KODK vs AMGN vs GILD vs XRXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

KODK
AMGN
GILD
XRX
StockMay 20May 26Return
Eastman Kodak Compa… (KODK)100570.6+470.6%
Amgen Inc. (AMGN)100143.3+43.3%
Gilead Sciences, In… (GILD)100172.2+72.2%
Xerox Holdings Corp… (XRX)10014.9-85.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: KODK vs AMGN vs GILD vs XRX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: AMGN and GILD are tied at the top with 2 categories each — the right choice depends on your priorities. Gilead Sciences, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. XRX and KODK also each lead in at least one category. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
KODK
Eastman Kodak Company
The Defensive Pick

KODK is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 1.68, Low D/E 35.1%, current ratio 3.14x
  • +122.5% vs XRX's -53.5%
Best for: sleep-well-at-night
AMGN
Amgen Inc.
The Income Pick

AMGN has the current edge in this matchup, primarily because of its strength in income & stability and growth exposure.

  • Dividend streak 15 yrs, beta 0.60, yield 2.9%
  • Rev growth 9.9%, EPS growth 88.2%, 3Y rev CAGR 11.8%
  • Beta 0.60, yield 2.9%, current ratio 1.14x
  • Beta 0.60 vs XRX's 2.68, lower leverage
Best for: income & stability and growth exposure
GILD
Gilead Sciences, Inc.
The Long-Run Compounder

GILD is the #2 pick in this set and the best alternative if long-term compounding and valuation efficiency is your priority.

  • 87.8% 10Y total return vs AMGN's 156.4%
  • PEG 0.15 vs AMGN's 5.01
  • 31.0% margin vs XRX's -14.1%
  • 16.1% ROA vs XRX's -10.8%, ROIC 23.4% vs -1.0%
Best for: long-term compounding and valuation efficiency
XRX
Xerox Holdings Corporation
The Growth Leader

XRX is the clearest fit if your priority is growth and value.

  • 12.9% revenue growth vs GILD's 2.4%
  • Lower P/E (5.1x vs 14.7x)
Best for: growth and value
See the full category breakdown
CategoryWinnerWhy
GrowthXRX logoXRX12.9% revenue growth vs GILD's 2.4%
ValueXRX logoXRXLower P/E (5.1x vs 14.7x)
Quality / MarginsGILD logoGILD31.0% margin vs XRX's -14.1%
Stability / SafetyAMGN logoAMGNBeta 0.60 vs XRX's 2.68, lower leverage
DividendsAMGN logoAMGN2.9% yield, 15-year raise streak, vs XRX's 23.7%
Momentum (1Y)KODK logoKODK+122.5% vs XRX's -53.5%
Efficiency (ROA)GILD logoGILD16.1% ROA vs XRX's -10.8%, ROIC 23.4% vs -1.0%

KODK vs AMGN vs GILD vs XRX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

KODKEastman Kodak Company
FY 2025
Other
92.7%$38M
Growth Products
7.3%$3M
AMGNAmgen Inc.
FY 2025
Other Products
20.6%$7.3B
Prolia
12.5%$4.4B
Repatha
8.5%$3.0B
Otezla
6.4%$2.3B
ENBREL
6.3%$2.2B
EVENITY
5.9%$2.1B
XGEVA
5.9%$2.1B
Other (8)
33.9%$12.0B
GILDGilead Sciences, Inc.
FY 2025
Products, Other HIV
79.7%$20.8B
Cell Therapy Products, Total Cell Therapy Product Sales
8.4%$2.2B
Trodelvy
5.4%$1.4B
Veklury
3.5%$911M
Other Products, Total Other product sales
3.1%$799M
XRXXerox Holdings Corporation
FY 2025
Service Arrangements
24.7%$1.7B
Maintenance
23.2%$1.6B
Manufactured Product, Other
21.2%$1.5B
Supplies, Paper And Other Sales
18.1%$1.3B
I T Solutions Segment
7.4%$523M
Rental And Other
3.6%$254M
Financial Service
1.8%$126M

KODK vs AMGN vs GILD vs XRX — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLKODKLAGGINGAMGN

Income & Cash Flow (Last 12 Months)

Evenly matched — KODK and GILD each lead in 2 of 6 comparable metrics.

AMGN is the larger business by revenue, generating $37.2B annually — 34.3x KODK's $1.1B. GILD is the more profitable business, keeping 31.0% of every revenue dollar as net income compared to XRX's -14.1%. On growth, XRX holds the edge at +26.7% YoY revenue growth, suggesting stronger near-term business momentum.

MetricKODK logoKODKEastman Kodak Com…AMGN logoAMGNAmgen Inc.GILD logoGILDGilead Sciences, …XRX logoXRXXerox Holdings Co…
RevenueTrailing 12 months$1.1B$37.2B$29.7B$7.4B
EBITDAEarnings before interest/tax$61M$15.6B$12.1B$330M
Net IncomeAfter-tax profit-$137M$7.8B$9.2B-$1.0B
Free Cash FlowCash after capex$466M$8.6B$10.3B$267M
Gross MarginGross profit ÷ Revenue+22.4%+71.5%+63.0%+25.7%
Operating MarginEBIT ÷ Revenue+3.6%+31.6%+38.2%-0.6%
Net MarginNet income ÷ Revenue-12.6%+20.9%+31.0%-14.1%
FCF MarginFCF ÷ Revenue+42.9%+23.1%+34.8%+3.6%
Rev. Growth (YoY)Latest quarter vs prior year+7.3%+5.8%+4.4%+26.7%
EPS Growth (YoY)Latest quarter vs prior year+813.5%+4.4%+54.8%-13.3%
Evenly matched — KODK and GILD each lead in 2 of 6 comparable metrics.

Valuation Metrics

XRX leads this category, winning 4 of 7 comparable metrics.

At 19.8x trailing earnings, GILD trades at a 14% valuation discount to AMGN's 23.1x P/E. Adjusting for growth (PEG ratio), GILD offers better value at 0.15x vs AMGN's 7.86x — a lower PEG means you pay less per unit of expected earnings growth.

MetricKODK logoKODKEastman Kodak Com…AMGN logoAMGNAmgen Inc.GILD logoGILDGilead Sciences, …XRX logoXRXXerox Holdings Co…
Market CapShares × price$1.4B$177.6B$166.4B$310M
Enterprise ValueMkt cap + debt − cash$1.3B$223.1B$183.4B$4.0B
Trailing P/EPrice ÷ TTM EPS-7.95x23.12x19.77x-0.29x
Forward P/EPrice ÷ next-FY EPS est.14.74x15.69x5.14x
PEG RatioP/E ÷ EPS growth rate7.86x0.15x
EV / EBITDAEnterprise value multiple23.97x14.08x16.95x14.71x
Price / SalesMarket cap ÷ Revenue1.29x4.83x5.65x0.04x
Price / BookPrice ÷ Book value/share1.78x20.60x7.44x0.45x
Price / FCFMarket cap ÷ FCF3.10x21.92x17.60x1.20x
XRX leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

GILD leads this category, winning 5 of 9 comparable metrics.

AMGN delivers a 89.4% return on equity — every $100 of shareholder capital generates $89 in annual profit, vs $-142 for XRX. KODK carries lower financial leverage with a 0.35x debt-to-equity ratio, signaling a more conservative balance sheet compared to XRX's 6.31x. On the Piotroski fundamental quality scale (0–9), GILD scores 9/9 vs XRX's 3/9, reflecting strong financial health.

MetricKODK logoKODKEastman Kodak Com…AMGN logoAMGNAmgen Inc.GILD logoGILDGilead Sciences, …XRX logoXRXXerox Holdings Co…
ROE (TTM)Return on equity-18.7%+89.4%+42.3%-142.4%
ROA (TTM)Return on assets-7.6%+8.6%+16.1%-10.8%
ROICReturn on invested capital+2.1%+14.8%+23.4%-1.0%
ROCEReturn on capital employed+1.6%+16.0%+25.1%-0.9%
Piotroski ScoreFundamental quality 0–97793
Debt / EquityFinancial leverage0.35x6.31x1.09x6.31x
Net DebtTotal debt minus cash-$87M$45.5B$17.0B$3.7B
Cash & Equiv.Liquid assets$337M$9.1B$7.6B$512M
Total DebtShort + long-term debt$250M$54.6B$24.6B$4.2B
Interest CoverageEBIT ÷ Interest expense0.79x5.02x8.87x-0.14x
GILD leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

KODK leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in GILD five years ago would be worth $22,418 today (with dividends reinvested), compared to $2,593 for XRX. Over the past 12 months, KODK leads with a +122.5% total return vs XRX's -53.5%. The 3-year compound annual growth rate (CAGR) favors KODK at 61.2% vs XRX's -33.4% — a key indicator of consistent wealth creation.

MetricKODK logoKODKEastman Kodak Com…AMGN logoAMGNAmgen Inc.GILD logoGILDGilead Sciences, …XRX logoXRXXerox Holdings Co…
YTD ReturnYear-to-date+67.7%+1.2%+10.9%-2.6%
1-Year ReturnPast 12 months+122.5%+22.8%+38.8%-53.5%
3-Year ReturnCumulative with dividends+318.6%+51.9%+82.4%-70.5%
5-Year ReturnCumulative with dividends+94.4%+46.2%+124.2%-74.1%
10-Year ReturnCumulative with dividends+20.7%+156.4%+87.8%-42.4%
CAGR (3Y)Annualised 3-year return+61.2%+15.0%+22.2%-33.4%
KODK leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — KODK and AMGN each lead in 1 of 2 comparable metrics.

AMGN is the less volatile stock with a 0.60 beta — it tends to amplify market swings less than XRX's 2.68 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KODK currently trades 95.2% from its 52-week high vs XRX's 34.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricKODK logoKODKEastman Kodak Com…AMGN logoAMGNAmgen Inc.GILD logoGILDGilead Sciences, …XRX logoXRXXerox Holdings Co…
Beta (5Y)Sensitivity to S&P 5001.68x0.60x0.66x2.68x
52-Week HighHighest price in past year$14.87$391.29$157.29$6.80
52-Week LowLowest price in past year$4.94$261.43$95.30$1.19
% of 52W HighCurrent price vs 52-week peak+95.2%+84.1%+85.2%+34.9%
RSI (14)Momentum oscillator 0–10076.239.452.674.8
Avg Volume (50D)Average daily shares traded1.3M2.5M5.8M5.6M
Evenly matched — KODK and AMGN each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — AMGN and XRX each lead in 1 of 2 comparable metrics.

Analyst consensus: AMGN as "Buy", GILD as "Buy", XRX as "Sell". Consensus price targets imply 332.5% upside for XRX (target: $10) vs 6.6% for AMGN (target: $351). For income investors, XRX offers the higher dividend yield at 23.69% vs KODK's 0.16%.

MetricKODK logoKODKEastman Kodak Com…AMGN logoAMGNAmgen Inc.GILD logoGILDGilead Sciences, …XRX logoXRXXerox Holdings Co…
Analyst RatingConsensus buy/hold/sellBuyBuySell
Price TargetConsensus 12-month target$350.76$161.88$10.25
# AnalystsCovering analysts38585
Dividend YieldAnnual dividend ÷ price+0.2%+2.9%+2.4%+23.7%
Dividend StreakConsecutive years of raises015110
Dividend / ShareAnnual DPS$0.02$9.45$3.19$0.56
Buyback YieldShare repurchases ÷ mkt cap+0.5%0.0%+1.2%0.0%
Evenly matched — AMGN and XRX each lead in 1 of 2 comparable metrics.
Key Takeaway

XRX leads in 1 of 6 categories (Valuation Metrics). GILD leads in 1 (Profitability & Efficiency). 3 tied.

Best OverallEastman Kodak Company (KODK)Leads 1 of 6 categories
Loading custom metrics...

KODK vs AMGN vs GILD vs XRX: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is KODK or AMGN or GILD or XRX a better buy right now?

For growth investors, Xerox Holdings Corporation (XRX) is the stronger pick with 12.

9% revenue growth year-over-year, versus 2. 4% for Gilead Sciences, Inc. (GILD). Gilead Sciences, Inc. (GILD) offers the better valuation at 19. 8x trailing P/E (15. 7x forward), making it the more compelling value choice. Analysts rate Amgen Inc. (AMGN) a "Buy" — based on 38 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — KODK or AMGN or GILD or XRX?

On trailing P/E, Gilead Sciences, Inc.

(GILD) is the cheapest at 19. 8x versus Amgen Inc. at 23. 1x. On forward P/E, Xerox Holdings Corporation is actually cheaper at 5. 1x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — KODK or AMGN or GILD or XRX?

Over the past 5 years, Gilead Sciences, Inc.

(GILD) delivered a total return of +124. 2%, compared to -74. 1% for Xerox Holdings Corporation (XRX). Over 10 years, the gap is even starker: AMGN returned +156. 4% versus XRX's -42. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — KODK or AMGN or GILD or XRX?

By beta (market sensitivity over 5 years), Amgen Inc.

(AMGN) is the lower-risk stock at 0. 60β versus Xerox Holdings Corporation's 2. 68β — meaning XRX is approximately 347% more volatile than AMGN relative to the S&P 500. On balance sheet safety, Eastman Kodak Company (KODK) carries a lower debt/equity ratio of 35% versus 6% for Xerox Holdings Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — KODK or AMGN or GILD or XRX?

By revenue growth (latest reported year), Xerox Holdings Corporation (XRX) is pulling ahead at 12.

9% versus 2. 4% for Gilead Sciences, Inc. (GILD). On earnings-per-share growth, the picture is similar: Gilead Sciences, Inc. grew EPS 1684% year-over-year, compared to -297. 8% for Eastman Kodak Company. Over a 3-year CAGR, AMGN leads at 11. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — KODK or AMGN or GILD or XRX?

Gilead Sciences, Inc.

(GILD) is the more profitable company, earning 28. 9% net margin versus -14. 7% for Xerox Holdings Corporation — meaning it keeps 28. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GILD leads at 40. 1% versus -0. 8% for XRX. At the gross margin level — before operating expenses — GILD leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is KODK or AMGN or GILD or XRX more undervalued right now?

On forward earnings alone, Xerox Holdings Corporation (XRX) trades at 5.

1x forward P/E versus 15. 7x for Gilead Sciences, Inc. — 10. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for XRX: 332. 5% to $10. 25.

08

Which pays a better dividend — KODK or AMGN or GILD or XRX?

All stocks in this comparison pay dividends.

Xerox Holdings Corporation (XRX) offers the highest yield at 23. 7%, versus 0. 2% for Eastman Kodak Company (KODK).

09

Is KODK or AMGN or GILD or XRX better for a retirement portfolio?

For long-horizon retirement investors, Amgen Inc.

(AMGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 60), 2. 9% yield, +156. 4% 10Y return). Eastman Kodak Company (KODK) carries a higher beta of 1. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMGN: +156. 4%, KODK: +20. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between KODK and AMGN and GILD and XRX?

These companies operate in different sectors (KODK (Industrials) and AMGN (Healthcare) and GILD (Healthcare) and XRX (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: KODK is a small-cap quality compounder stock; AMGN is a mid-cap quality compounder stock; GILD is a mid-cap quality compounder stock; XRX is a small-cap income-oriented stock. AMGN, GILD, XRX pay a dividend while KODK does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

KODK

Quality Business

  • Sector: Industrials
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 13%
Run This Screen
Stocks Like

AMGN

Dividend Mega-Cap Quality

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 12%
Run This Screen
Stocks Like

GILD

Dividend Mega-Cap Quality

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 18%
  • Dividend Yield > 0.9%
Run This Screen
Stocks Like

XRX

High-Growth Disruptor

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 13%
  • Gross Margin > 15%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform KODK and AMGN and GILD and XRX on the metrics below

Revenue Growth>
%
(KODK: 7.3% · AMGN: 5.8%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.